<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204712">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000259</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-08391-11</org_study_id>
    <secondary_id>R01DA008391</secondary_id>
    <secondary_id>R01-08391-11</secondary_id>
    <nct_id>NCT00000259</nct_id>
  </id_info>
  <brief_title>Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11</brief_title>
  <official_title>Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to conduct experiments to examine subjective and reinforcing
      effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug
      abusers and preference procedures will be used to assess reinforcing effects. Comparisons
      between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To examine
      sevoflurane versus isoflurane inhalation at subanesthetic concentrations on mood, pain, and
      psychomotor performance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <completion_date type="Actual">November 1997</completion_date>
  <primary_completion_date type="Actual">November 1997</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>30 min of inhalation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects underwent a 3 min cold immersion test at 30 min of inhalation and then provided response to pain intensity questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychomotor performance</measure>
    <time_frame>Baseline, 5 min of inhalation; 5, 30, 60 minutes recovery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects underwent psychomotor testing at baseline, during inhalation, and during recovery post inhalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive performance</measure>
    <time_frame>Baseline, every 5 min during inhalation, 5, 30, &amp; 60 min during recovery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject underwent memory, sedation, visual analog, and drug effects testing</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject inhales no drug (100% oxygen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.6% sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15% Nitrous oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>30% Nitrous oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 % Nitrous oxide</intervention_name>
    <arm_group_label>15% Nitrous oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3 % Sevoflurane</intervention_name>
    <arm_group_label>0.3% sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30% Nitrous oxide</intervention_name>
    <arm_group_label>30% Nitrous oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.6% Sevoflurane</intervention_name>
    <arm_group_label>0.6% sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Please contact site for information.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Zacny, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago, Anesthesia &amp; Critical Care</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sevoflurane</keyword>
  <keyword>nitrous oxide</keyword>
  <keyword>subjective effects</keyword>
  <keyword>healthy volunteer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitrous Oxide</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
